Non Muscle Invasive Bladder Transitional Cancer (NMIBC) and Muscle Invasive Bladder Transitional Cancer (MIBC)/invasive have different gene profile and clinical course. NMIBC prognosis is not completely predictable, since the relapse rate is higher than 20%, even in the form of MIBC. The aim of this study is to evaluate if UTR expression can discriminate between NMIBC and MIBC and predict the risk of relapses in NMIBCs.
Franco, R., Zappavigna, S., Gigantino, V., Luce, A., Cantile, M., Cerrone, M., Facchini, G., Perdonà, S., Pignata, S., Di Lorenzo, G., Chieffi, S., Vitale, G., De Sio, M., Sgambato, A., Botti, G., Yousif, A., Novellino, E., Grieco, P., Caraglia, M., Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion, <<JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH>>, 2014; 33 (1): N/A-N/A. [doi:10.1186/1756-9966-33-48] [http://hdl.handle.net/10807/125995]
Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion
Sgambato, Alessandro;
2014
Abstract
Non Muscle Invasive Bladder Transitional Cancer (NMIBC) and Muscle Invasive Bladder Transitional Cancer (MIBC)/invasive have different gene profile and clinical course. NMIBC prognosis is not completely predictable, since the relapse rate is higher than 20%, even in the form of MIBC. The aim of this study is to evaluate if UTR expression can discriminate between NMIBC and MIBC and predict the risk of relapses in NMIBCs.
| File | Dimensione | Formato | |
|---|---|---|---|
|
unpaywall-bitstream-1222155013.pdf
accesso aperto
Tipologia file ?:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
1.84 MB
Formato
Adobe PDF
|
1.84 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
